USE OF INDURACIN, A LONG-ACTING NICOTINIC -ACID FORMULATION, TO CORRECT ATHEROGENETIC DYSLIPIDEMIAS

The hypolipidemic effects of induracin, a new long-acting nicotinic ac id dosage form based on the waxy matrix, and its tolerance were studie d in 31 patients with Types IIa and IIb hyperlipoproteinemias in a 6-m onth blind crossover study. There were decreases in the levels of tota l cholesterol by 9-13% and low density lipoprotein cholesterol by 12-2 2%, an increase in high density lipoprotein cholesterol by 12-15%, and a good dynamics in the ratio of blood lipid-transport proteins - a 12 -16% increase to the levels of apoprotein AI to a 29% decrease in thos e of apoprotein B. The drug is well tolerated by patients and may be r ecommended for correction of antherogen dyslipidemias.